In Vivo Models of Inflammation

  • Douglas W. Morgan
  • Lisa A. Marshall

Part of the Progress in Inflammation Research book series (PIR)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Wim B. van den Berg, Leo A. B. Joosten
    Pages 51-75
  3. E. Jonathan Lewis, Jill Bishop, Anna K. Greenham
    Pages 77-92
  4. James D. Winkler, Jeffrey R. Jackson, Tai-Ping Fan, Michael P. Seed
    Pages 93-109
  5. William M. Selig, Richard W. Chapman
    Pages 111-135
  6. Marsha A. Wills-Karp, Andrea Keane-Myers, Stephen H. Gavett, Douglas Kuperman
    Pages 137-158
  7. David C. Underwood
    Pages 159-177
  8. Kenneth M. Tramposch
    Pages 179-204
  9. Sreekant Murthy, Anne Flanigan
    Pages 205-236
  10. Elora J. Weringer, Ronald P. Gladue
    Pages 237-263
  11. Charles G. Orosz, M. Elaine Wakely, Ginny L. Bumgardner, Elora J. Weringer
    Pages 265-290
  12. David S. Grass
    Pages 291-305
  13. Karen M. Anderson, Sandhya S. Nerurkar, Michael R. Briggs
    Pages 307-332
  14. Kenneth N. Litwak, Howard C. Hughes
    Pages 333-336
  15. Back Matter
    Pages 337-347

About this book


Purpose of In vivo Models of Inflammation is to provide the biomedical researcher in both the pharmaceutical industry and academia with a description of the state of the art animal model systems used to emulate diseases with components of inflammation. The aim of this second edition is to act as a complement to the first by describing and updating the standard models that are most utilized for specific disease areas. In addition, this 2nd edition includes new models exploring emerging areas of inflammation research.

It provides detailed descriptions of the methodologies and uses of the most significant models. This includes current information regarding agents that demonstrate efficacy, those that do not and those that can be used as standard controls. The focus remains on those models that serve as pre-clinical correlates to human disease as well as those that represent components of the inflammatory response.

New approaches to the development of future models in selected therapeutic areas have been highlighted. The focus on novel technologies that are vital for innovative in vivo research has also been expanded to include chapters on the use of transgenic and gene transfer technologies, nanotechnology, and stem cells.

The book provides the scientist with an up-to-date reference manual for selecting the best animal model for their specific question. Chapters describing current regulations in the United States, United Kingdom, and Japan are also included.


Arthritis Asthma Cardiovascular diseases Gene transfer technology Skin inflammation Stem cells cancer cell inflammation neuroinflammation skin

Editors and affiliations

  • Douglas W. Morgan
    • 1
  • Lisa A. Marshall
    • 2
  1. 1.Cancer ResearchAbbott LaboratoriesAbbott ParkUSA
  2. 2.Department of ImmunologySmithKline Beecham PharmaceuticalsKing of PrussiaUSA

Bibliographic information